A Phase I Clinical Study to Evaluate the Tolerance and Safety of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesion(s) (CIN 2 and 3)
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
adverse events
weeks 1, 2, 3 and 4
Yes
Michel Bossens, MD, PhD
Principal Investigator
Erasme Hospital - Laboratoire de recherche en reproduction humaine
Belgium: Federal Agency for Medicinal Products and Health Products
MI-COL-CI01
NCT00989443
May 2010
Name | Location |
---|